Golden Finance reported that according to ai_9684xtpa analysis, BIO Protocol has received US$30.2 million in funding: two rounds of private placement, with a total financing of US$2.3 million, and valuations of US$35 million and US$69 million respectively; There were three rounds of public financing (i.e. BIO Genesis auction), raising a total of US$27.9 million, and the three rounds of valuations were US$85 million/US$142 million/US$219 million respectively. Currently, BIO has launched pre-market trading on Bybit and Bitget. Based on the pre-market average price of $0.9659 on the two major platforms at 12.29 22:00, BIO FDV is approximately US$3.2 billion. Private investors: account for 13.60% of the total supply; public investors: account for 20.00% of the total supply. The costs are as follows: private placement · Before seed round: cost is about US$0.01054, current floating profit is 91.62 times; · In the seed round: cost is about US$0.02078, current floating profit is 46.48 times; public offering · Round 1: The cost is about US$0.0256, and the current floating profit is 37.73 times; · Round 2: Cost is approximately US$0.04277, current floating profit is 22.58 times; · Round 3: The cost is approximately US$0.06596, and the current floating profit is 14.64 times.